newsfilter
← Latest News
PR Newswire·

AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures

Study results show higher rates of successful procedure completion and higher patient and clinician satisfaction scores compared to topical local anesthesia alone HAYWARD, Calif., March 31, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACR